Elicio Therapeutics to Host Virtual Key Opinion Leader Event
BOSTON — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a pioneering biotechnology company focused on developing novel immunotherapies for cancer treatment, is excited to announce a virtual key opinion leader (KOL) event. This engagement is set for an afternoon session aimed at discussing the significant unmet needs and current therapeutic landscape for mutant-KRAS-driven pancreatic ductal adenocarcinoma (PDAC), an aggressive and often lethal type of cancer.
Event Insights from Leading Experts
The virtual event will feature several insightful presentations from leading experts in oncology. Among the prominent speakers are:
- Darrell Irvine, Ph.D. - Renowned for his work at The Scripps Research Institute and Howard Hughes Medical Institute.
- Eileen O’Reilly, M.D. - A distinguished gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center.
Focus on Elicio’s Innovative Treatments
This event will delve into Elicio's proprietary lymph node-targeting amphiphile (AMP) platform, which is fundamental to the development of their promising immunotherapies. The spotlight will be on ELI-002, which is designed as a therapeutic vaccine specifically aimed at overcoming challenges posed by immune evasion in cancer patients. The company is currently conducting a randomized Phase 2 trial evaluating ELI-002's effectiveness against mKRAS-driven PDAC, with an interim analysis on disease-free survival anticipated soon.
About the Experts Presenting
Darrell Irvine, Ph.D.
Dr. Darrell Irvine is a prominent figure in cellular immunology and vaccine development. His expertise lies in utilizing engineering tools to develop innovative strategies for immunotherapy and cancer treatments. His dedication to advancing our understanding of immune responses positions him as a key speaker in discussing Elicio's innovative approaches to combating cancer.
Eileen M. O’Reilly, M.D.
Dr. Eileen O’Reilly is a highly respected oncologist and educator. Her research integrates molecular and genetic therapies for treating pancreatic cancer, which aligns directly with the goals of Elicio Therapeutics. As a leader in clinical trials for pancreatic cancer, her insights will offer valuable perspectives on the integration of new therapies into current practice.
Overview of Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) stands at the forefront of developing innovative cancer immunotherapies. The company aims to make strides in treating high-prevalence cancers, including those associated with mutant KRAS mutations. With a focus on off-the-shelf vaccine solutions that protect patients from relapse, Elicio seeks to leverage its AMP technology to enhance T-cell responses.
ELI-002 is a lead candidate within their pipeline, specifically targeting the most common KRAS mutations which contribute to about 25% of all solid tumors. The potential benefits of ELI-002 and similar vaccines include not only cost-effectiveness but also rapid availability, essential in providing timely treatment for patients at high risk of cancer recurrence.
Looking Ahead: The Future of ELI-002
As Elicio Therapeutics continues its groundbreaking work, plans are underway to explore additional indications for its lead product candidate, ELI-002, to target other diseases caused by mKRAS mutations, including lung cancer. The company is also investing in additional candidates, ELI-007 and ELI-008, focusing on cancers driven by BRAF mutations and p53 mutations respectively.
Understanding the AMP Platform
Elicio's AMP platform plays a crucial role in delivering immunotherapies directly to the lymph nodes, which are central to the immune response. By concentrating on lymph node-specific delivery mechanisms, Elicio aims to significantly enhance the effectiveness of its immunotherapeutics, promoting durable immune responses and better patient outcomes.
Frequently Asked Questions
What is the purpose of Elicio's KOL event?
The KOL event is designed to discuss the unmet medical needs in treating mutant-KRAS-driven pancreatic cancer and to present insights on Elicio's novel immunotherapy approaches.
Who are the featured speakers at the event?
Expert presenters include Darrell Irvine, Ph.D., and Eileen O’Reilly, M.D., who will share insights from their extensive experience in immunology and oncology.
What is ELI-002?
ELI-002 is an AMP-powered therapeutic vaccine candidate aimed at overcoming immune evasion in mutant KRAS-driven cancers, currently evaluated in clinical trials.
How does the AMP platform work?
Elicio's AMP platform facilitates targeted delivery of immunotherapeutics to lymph nodes, enhancing immune responses through precise engagement of immune cells.
What future plans does Elicio Therapeutics have?
Elicio aims to explore additional cancer types linked to KRAS mutations and develop more off-the-shelf vaccine candidates, enhancing cancer treatment options.
